Researchers & Healthcare Professionals

Epigenetics in Hematologic Malignancies: Pathogenesis and Therapy

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Internet Release Date: February 22, 2012
Credit Available Until: August 22, 2013
Target Audience: Hematologists, oncologists, nurses, social workers and other healthcare professionals
Access: Virtual Lecture

Activity Purpose

This free activity, entitled "Epigenetics in Hematologic Malignancies: Pathogenesis and Therapy," consists of a program overview, 5 presentations with Q&A, a Learning Assessment, and an Evaluation form. The content of this virtual lecture is derived from a symposium presented on December 9, 2011, in San Diego, California. It is designed for hematologists, oncologists, nurses, social workers and other healthcare professionals who wish to enhance their knowledge of advances in epigenetic research and implications in treating patients with hematologic malignancies.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe how epigenetic changes affect gene expression and contribute to malignant changes in blood cancer cells
  • Discuss new strategies for the development of blood cancer therapies which inhibit factors that produce epigenetic changes in blood cancer cells
  • Discuss the therapeutic potential of targeting epigenetic changes as they relate specifically to leukemia, lymphoma and myeloma
  • Utilize the information presented from current trials and best practices focusing on epigenetic therapies to better manage their patients with hematologic malignancies


Stephen B. Baylin, MD
Deputy Director, The Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins
Research Professor of Oncology
Johns Hopkins University
Baltimore, MD

James E. Bradner, MD
Attending Physician, Hematology-Oncology
Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Jean-Pierre Issa, MD
Professor of Medicine
Director, Fels Institute for Cancer
Research & Molecular Biology
Temple University School of Medicine
Philadelphia, PA

Ross L. Levine, MD
Associate Member, Human Oncology & Pathogenesis Program
Associate Attending Physician, Leukemia Service, Department of Medicine
Geoffrey Beene Junior Faculty Chair
Memorial Sloan-Kettering Cancer Center
Assistant Professor of Medicine and Ce./Developmental Biology
Weill Cornell Medical College
New York, NY

Jonathan D. Licht, MD
Johanna Dobe Professor and Chief
Division of Hematology/Oncology
Associate Director, Clinical Sciences
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL

Sponsors and Supporters

This activity was jointly sponsored by RMEI, LLC and Postgraduate Institute for Medicine in collaboration with The Leukemia & Lymphoma Society and was supported by educational grants from Millennium: The Takeda Oncology Company, Celgene Corporation and Allos Therapeutics, Inc.

last updated on Wednesday, September 04, 2013